Cleveland BioLabs (CBLI) Earning Somewhat Negative Press Coverage, Study Shows

News articles about Cleveland BioLabs (NASDAQ:CBLI) have trended somewhat negative recently, according to Alpha One Sentiment Analysis. The research firm, a unit of Accern, identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cleveland BioLabs earned a media sentiment score of 0.00 on Alpha One’s scale. Alpha One also assigned media coverage about the biotechnology company an impact score of 100 out of 100, meaning that recent press coverage is extremely likely to have an effect on the company’s share price in the near future.

Here are some of the headlines that may have impacted AlphaOne Sentiment’s analysis:

Shares of Cleveland BioLabs (NASDAQ:CBLI) traded up 2.39% during mid-day trading on Friday, reaching $3.43. The company had a trading volume of 131,028 shares. The stock has a 50 day moving average of $3.00 and a 200-day moving average of $1.97. Cleveland BioLabs has a one year low of $1.22 and a one year high of $5.55. The firm’s market capitalization is $37.69 million.

Cleveland BioLabs (NASDAQ:CBLI) last issued its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. Cleveland BioLabs had a negative net margin of 75.04% and a negative return on equity of 21.29%. The business had revenue of $0.58 million for the quarter. Equities analysts predict that Cleveland BioLabs will post ($0.16) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/05/20/somewhat-negative-press-coverage-extremely-likely-to-affect-cleveland-biolabs-cbli-stock-price-updated.html.

Cleveland BioLabs Company Profile

Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.

12 Month Chart for NASDAQ:CBLI

Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply